how-we-partner human-behavioral-insights 
Pharma Marketing Network
OCTOBER 5, 2020
An interview with Mark Bard, Co-Founder of The DHC Group and Justin Grossman, CEO/Managing Partner, meltmedia. In response to this week’s DHC Virtual Summit with Novartis, Mark Bard, Co-founder/Managing Partner, DHC, talked one-on-one with Justin Grossman about how the COVID pandemic will change the world of digital healthcare marketing.
Pharma Marketing Network
OCTOBER 5, 2020
An interview with Mark Bard, Co-Founder of The DHC Group and Justin Grossman, CEO/Managing Partner, meltmedia. In response to this week’s DHC Virtual Summit with Novartis, Mark Bard, Co-founder/Managing Partner, DHC, talked one-on-one with Justin Grossman about how the COVID pandemic will change the world of digital healthcare marketing.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
NOVEMBER 30, 2023
In this interview, Xtalks spoke with two industry experts from Alira Health , Giulia Pierini , Principal of Patient Engagement, and Eduardo Perez-Guagnelli , PhD, Patient-Centric Co-Design Lead, about how life sciences companies can adopt patient-centric co-design in their product development. How was this discrepancy addressed?
The Pharma Data
DECEMBER 13, 2020
Roche and Genentech’s global footprint and deep expertise in oncology makes them the perfect partner for us to execute the broad development and commercialization of RLY-1971.”. global head of pharma partnering, Roche. “We To learn more about the first-in-human clinical trial of RLY-1971, please visit here.
XTalks
AUGUST 5, 2020
Coupling single cell omics with other omics technologies and machine learning tools such as artificial intelligence (AI) can provide key insights about cellular and molecular targets that drive diseases. Feature barcoding using gel beads. Leading Innovations in Single Cell Technology. Single Cell Omics and Computational Analysis.
XTalks
DECEMBER 22, 2021
The development and widespread adoption of new technologies is key to revolutionizing the way we diagnose, prevent, treat and manage disease. Fast forward to more recent times, companies like Moderna as well as Pfizer’s COVID-19 vaccine partner BioNTech had been working on mRNA-based therapeutics, including vaccines, for just over a decade.
The Pharma Data
FEBRUARY 8, 2021
Insights from the ACIS study regarding differences in benefit for specific patient subgroups treated with the combination warrant additional evaluation.”. Effect of ERLEADA ® on Other Drugs — ERLEADA ® is a strong inducer of CYP3A4 and CYP2C19, and a weak inducer of CYP2C9 in humans. ADVERSE REACTIONS. ADVERSE REACTIONS.
Expert insights. Personalized for you.
98 
Let's personalize your content